All In MedTech

FDA Clearance Tracker · P160001-S038

OBALON BALLOON SYSTEM

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: May 29, 2019 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

May 29, 2019

Approved

Time to decision

40 days

Received Apr 19, 2019. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Normal 180 Day Track No User Fee

Device class

Class III

The decision

FDA number
P160001-S038
Device name
OBALON BALLOON SYSTEM
Applicant
Medtimo, Inc.
Applicant location
Eden Prairie, MN
Received
Apr 19, 2019
Decided
May 29, 2019
Decision
Approved
Supplement type
Normal 180 Day Track No User Fee
Reason for supplement
Postapproval Study Protocol
Original approval
P160001

Device type

Device class
Class III

Every decision under product code LTI

FDA's approval statement

As written in FDA's record.

This PMA includes the evaluation of the Obalon Navigation Touch System (NTS) implant procedure and device. P160001 was approved on 9/08/2016 , and P160001/S020 was approved on 12/20/2018 with the following conditions of approval: In addition to the Annual Report requirements, you must provide the following data in post-approval study (PAS) reports for each PAS listed below. Separate PAS Progress Reports must be submitted for each study every six (6) months during the first two (2) years of the study and annually thereafter, unless otherwise specified by FDA. Each report, identified as a "PMA Post-Approval Study Report" in accordance with how the study is identified below and bearing the applicable PMA reference number, should be submitted to the address below.1. PMA Post-Approval Study – Obalon NTS Post-Approval Study: On December 18, 2018 (by interactive e-mail review), you agreed to conduct a post-approval study as follows: The Obalon Navigation Touch System (NTS) Post-Approval Study is a prospective, observational, open-label, multi-center study designed to evaluate the risk of esophageal inflation during Obalon balloon administration in eligible patients. This is a stand-alone, new enrollment study with primary data collection, with no retrospective data acquisition from other sources (i.e., retrospective chart review; data abstraction from existing registries or other data sources). Safety of balloon administration is the focus of this short-term study. Therefore, follow-up of participants ends on the day of balloon administration. However, patients who experience any adverse events related to balloon administration will be followed until resolution of the adverse event. Subjects may re-enter the study for additional balloons as indicated.The co-primary endpoints are: esophageal inflation; and NTS Success defined as balloon inflation in the stomach with the use of the NTS only (without radiography) or correctly determining failed balloon transit (device in the esophagus) as confirmed by endoscopic removal.The study will include a minimum of 3,951 evaluable balloon administrations with at least 1,317 balloon administrations for an individual balloon administration number (1st, 2nd or 3rd). An evaluable balloon administration is achieved if the device capsule passes the upper esophageal sphincter. The sample size of 3,951 is based on the higher sample size required (between the co-primary endpoints) for the esophageal inflation endpoint. The study will enroll a minimum of 1,400 subjects at up to 40 U.S. sites. A participating physician must not exceed 792 (20% of the total) evaluable balloon administrations or 264 for individual balloon type (Balloon 1, 2, or 3). The study will enroll a minimum of 1,000 subjects The first co-primary endpoint, esophageal inflation, is met if none of the Obalon Balloon administrations in the study resulted in an esophageal inflation and the 97.5% one-sided upper exact confidence bound for the estimated esophageal inflation rate is less than 0.1% based on 80% power. The second co-primary endpoint, NTS Success, is met if the one-sided 97.5% lower exact confidence bound is greater than 97% based on 80% power.Other study endpoints include the following: individual device or procedure related adverse event rates; Product Performance Observations (PPO) rates; and percentage of balloon administrations with the following Obalon Navigation System Stomach Location Indicators: Capsules significantly offsets (left lateral) from initial vertical track; Capsules track accelerates; Capsule rotates from vertical to horizontal configuration; and Capsule up/down movement with deep respiration (breath).

Source documents

Other decisions for Medtimo, Inc.

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.